Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Peter Langmuir, MD
Incyte Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
90 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Finsen Centre National Hospital
Copenhagen, Denmark
- Institut Bergonie
Bordeaux, France
- Centre Georges Fran�ois Leclerc
Dijon, France
- Centre Antoine Lacassagne
Nice, France
- A.P.H. Paris Hopital Cochin
Paris, France
- Hospital Saint Louis
Paris, France
- Institut Universitaire Du Cancer de Toulouse Oncopole
Toulouse, France
- Universitatsklinikum Koln
Cologne, Germany
- University Medical Center Freiburg
Freiburg im Breisgau, Germany
- University Medical Centre Hamburg-Eppendorf, Centre of Oncology
Hamburg, Germany
- University Hospital Grosshadern Munich
Munich, Germany
- Universitaetsklinikum in Tubingen
Tübingen, Germany
- Ha Emek Medical Center
Afula, Israel
- Rambam Health Care Campus
Haifa, Israel
- Hadassah Hebrew University Medical Center Ein Karem Hadassah
Jerusalem, Israel
- Rabin Medical Center - Beilinson Hospital
Petah Tikva, Israel
- Assaf Harofeh Medical Center
Ẕerifin, Israel
- L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola Ï¿½ Malpighi
Bologna, Italy
- Fondazione del Piemonte Per L Oncologia Ircc Candiolo
Candiolo, Italy
- Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
- Istituto Nazionale Tumori Irccs Fondazione Pascale
Naples, Italy
- Istituto Nazionale Tumori Regina Elena Irccs
Roma, Italy
- Centro Ricerche Cliniche Di Verona (crc)
Verona, Italy
- National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
- Kanazawa University Hospital
Ishikawa, Japan
- Kobe University Hospital
Kobe, Japan
- Tohoku University Hospital
Sendai, Japan
- Keio University Hospital
Shinjuku-ku, Japan
- Shizuoka Cancer Center
Shizuoka, Japan
- Kanagawa Cancer Center
Yokohama, Japan
- National Cancer Center
Goyang-si, South Korea
- Seoul National University Bundang Hospital
Seongnam-si, South Korea
- Samsung Medical Center
Seoul, South Korea
- Severance Hospital Yonsei University Health System
Seoul, South Korea
- Hospital Clinic I Provincial
Barcelona, Spain
- Hospital General Universitario Vall D Hebron
Barcelona, Spain
- Centro Integral Oncologico Clara Campal (ciocc)
Madrid, Spain
- Hospital Regional Universitario de Malaga
Málaga, Spain
- Clinica Universidad de Navarra (cun)
Pamplona, Spain
- Hospital Universitario Marques de Valdecilla
Santander, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Oct 2019
- Primary completion
- 29 Mar 2022
- Completion
- 29 Mar 2022
- Last update posted
- 4 Nov 2025
- Registered enrollment
- 111
- Registry id
- NCT03822117
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.